Chicago Medical School

Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath’s Board of Directors

Retrieved on: 
Martedì, Maggio 28, 2024
Oncology, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, M.A, Yale University, Eli Lilly and Company, Faculty, Consultant, Liver, Internal medicine, Addiction medicine, Therapy, Microbiology, Chicago Medical School, Internal, Molecular Immunology, System, Acquisition, Cornell University, Boston University

“We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors.

Key Points: 
  • “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors.
  • “Dr.
  • “I am excited to be joining Delcath’s Board of Directors at this crucial time in the Company’s growth and evolution,” said Dr. Martell.
  • “I look forward to supporting the Delcath team both in its near-term commercial goals and longer-term clinical development strategy.”

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 9, 2024
Chicago Medical School, Sale, University, Patient, Rutgers University, ATS, Alopecia areata, Kinetics, Skin, European Patent Convention, Research, MD, Doctor of Philosophy, Conference, KOL, Potential, ADS, Week, Patent, Data, Dupilumab, University of Rochester, Translational medicine, International Examiner, Magnetic resonance, Atopic dermatitis, Harvard Medical School, ASLN, TREK, Clutch (eggs), Interim, Biology, American Thoracic Society, Associate, Emergency medicine, EPO, SAN, COPD, Pharmaceutical industry

SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.
  • Research and development expenses were $5.9 million for the first quarter of 2024 compared to $14.1 million for the first quarter of 2023.
  • General and administrative expenses were $3.4 million for the first quarter of 2024 compared to $4.0 million for the first quarter of 2023.
  • Net loss attributable to stockholders for the first quarter of 2024 was $9.9 million compared to a net loss of $19.1 million for the first quarter of 2023.

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

Retrieved on: 
Martedì, Maggio 7, 2024
Chicago Medical School, Itch, University, Patient, Skin, MD, Doctor of Philosophy, KOL, Potential, Week, Data, University of Rochester, Physician, Magnetic resonance, Atopic dermatitis, ASLN, Clutch (eggs), SAN, Pharmaceutical industry

“The numbers we have reported from the interim analysis of the TREK-DX study are unprecedented in previous biologics studies in atopic dermatitis (AD) and the new data continue to support our original conclusions announced in April.

Key Points: 
  • “The numbers we have reported from the interim analysis of the TREK-DX study are unprecedented in previous biologics studies in atopic dermatitis (AD) and the new data continue to support our original conclusions announced in April.
  • During the KOL event today, Company management will present new data on investigator-assessed and patient-reported secondary endpoints and data from the subgroup of patients with prior inadequate response to dupilumab.
  • Discontinuation rates were lower for patients treated with eblasakimab (13%, 2/15) compared to those on placebo (43%, 3/7).
  • Waterfall plots of individual patient responses show clear and consistent improvements in almost all patients treated with eblasakimab versus placebo.

Groundbreaking Non-Invasive Migraine and Cluster Headache Treatment Now Offered Nationally by Dr. David Mahjoubi.

Retrieved on: 
Martedì, Marzo 26, 2024
Vagus nerve, Learning, Headache, Inflammation, Patient, Migraine, Cluster headache, University, Hope, USC, Chicago Medical School, Nerve conduction study, Nociception, Skin, LOS, Pain, Multimedia, University of Southern California, UCLA

LOS ANGELES, March 26, 2024 /PRNewswire-PRWeb/ -- Dr. David Mahjoubi is proud to offer an innovative and effective non-invasive treatment for migraine and cluster headaches- gammaCore Sapphire™. This revolutionary therapy marks a significant milestone in the pursuit of effective and holistic solutions for chronic headache sufferers.

Key Points: 
  • LOS ANGELES, March 26, 2024 /PRNewswire-PRWeb/ -- Dr. David Mahjoubi is proud to offer an innovative and effective non-invasive treatment for migraine and cluster headaches - gammaCore Sapphire™.
  • "We are thrilled to offer gammaCore Sapphire™ as part of our comprehensive approach to wellness, says Dr. David Mahjoubi, a board-certified Anesthesiologist.
  • Migraine and cluster headaches affect millions of individuals worldwide, often leading to debilitating pain and disrupting daily activities.
  • The clinic also offers a range of other services, including IV and Ketamine therapy , and now gammaCore Sapphire™ for migraine and cluster headache relief.

The Inner Circle Acknowledges, Howard Siegel, MD as a Pinnacle Lifetime Member

Retrieved on: 
Lunedì, Febbraio 19, 2024
Dedication, Psychology, Inner circle, Multimedia, Chicago Medical School, Medical degree, Associate, Mount Sinai Beth Israel, University, Hepatitis, Society, Gastrointestinal Endoscopy, Specialization, Mentorship, Memory, Internal medicine, Health, Patient, Diagnosis, Gastroenterology, Ulcer, Esophagus, Veterans Health Administration, P.C, Nursing

NEW YORK, Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Howard Siegel, MD is acknowledged as a Pinnacle Lifetime Member for his contributions as a Gastroenterologist with 57 Years of Dedication and Expertise.

Key Points: 
  • NEW YORK, Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Howard Siegel, MD is acknowledged as a Pinnacle Lifetime Member for his contributions as a Gastroenterologist with 57 Years of Dedication and Expertise.
  • His unwavering commitment to patient care has made him a respected figure in the field of gastroenterology.
  • Dr. Siegel's practice, Manhattan Internal Medicine Associates, P.C., is renowned for providing advanced and personalized gastroenterological care.
  • In memory of his esteemed mentors, Dr. Siegel pays tribute to the invaluable guidance and support received from Dr. Edward King, MD, and Dr. David.

The Ketamine Healing Clinic Announces their At-Home Depression, Anxiety & Chronic Pain Ketamine Program- Nutrabrain™

Retrieved on: 
Mercoledì, Dicembre 13, 2023
UCLA, USC, Depression, Chronic pain, Medical director, Chicago Medical School, Migraine, Patient, Multimedia, Pharmacy, LOS, University, Ketamine, Anxiety, MD, PTSD, Mental health, Alcoholism, University of Southern California, Neuropathic pain, Arthritis, Medical device, Hospital

LOS ANGELES, Dec. 13, 2023 /PRNewswire-PRWeb/ -- The Ketamine Healing Clinic of Los Angeles and Orange County, known worldwide for its pioneering work in ketamine therapy, is proud to announce its latest offering: the at-home Nutrabrain program. This innovative protocol sets a new standard in ketamine therapy, providing patients with a comprehensive and accessible solution for mental health, chronic pain, and alcoholism needs. Dr. David Mahjoubi, MD, the esteemed Medical Director of the Ketamine Healing Clinic, has long been recognized as a trailblazer in the field of ketamine treatment. With the introduction of the Nutrabrain program, Dr. Mahjoubi aims to revolutionize the way patients receive and benefit from ketamine therapy. The Nutrabrain protocol offers patients a seamless and effective treatment journey. First, patients will need to complete a video consultation with Dr. David Mahjoubi, MD, to determine the most suitable treatment plan. After the prescription is electronically wired to the pharmacy, the Ketamine is sent to the patient, ensuring a hassle-free experience. This supply will last for two treatments per week over four weeks, constituting the Nutrabrain protocol. If patients wish to continue the treatment, they can schedule another video consultation with Dr. David Mahjoubi and receive another one-month supply. This step can be repeated three times, after which patients qualify for a 90-day prescription supply. A minimum of four weeks between consultations is required. The protocol and 3-month prescription can allow for continued treatment and sustained relief, in the comfort of one's home, from a range of conditions, including anxiety, depression, PTSD, chronic pain, psychiatric medication tapering, migraines, neuropathic pain and arthritic pain. The Ketamine Healing Clinic of Los Angeles and Orange County is at the forefront of this innovative treatment approach, providing a safe and convenient way for patients to undergo transformative therapy. With a team of highly skilled professionals, the clinic is committed to delivering personalized care and achieving optimal outcomes for every individual. To learn more about the Nutrabrain protocol and start a journey towards improved mental health, please visit http://www.ketaminehealing.com/at-home-ketamine/.

Key Points: 
  • Dr. David Mahjoubi, MD, the esteemed Medical Director of the Ketamine Healing Clinic, has long been recognized as a trailblazer in the field of ketamine treatment.
  • Dr. Mahjoubi founded The Ketamine Healing Clinic of Los Angeles in 2014, making him one of the longest-running Ketamine clinics in the world.
  • For information on the Ketamine Healing Clinic of Los Angeles and the Ketamine Healing Clinic of Orange County please visit the website at http://www.ketaminehealing.com , or call (424) 278-4241 or (949) 514-8261.
  • Dr. David Mahjoubi, Ketamine Healing Clinic of Los Angeles & Orange County, (424) 278-4241, [email protected] , https://www.ketaminehealing.com/
    View original content to download multimedia: https://www.prweb.com/releases/the-ketamine-healing-clinic-announces-the...

Dr. Faris Abusharif Scholarship for Medical Students Opens Doors for Aspiring Physicians

Retrieved on: 
Lunedì, Dicembre 11, 2023
Medicine, Anesthesiology, Pain management, Student, GPA, Hope, Chicago Medical School, Education, Nursing, Pharmaceutical industry

ORLAND PARK, Ill., Dec. 11, 2023 /PRNewswire/ -- The esteemed Dr. Faris Abusharif Scholarship for Medical Students is now accepting applications, offering a significant opportunity for budding medical professionals to propel their academic journey.

Key Points: 
  • ORLAND PARK, Ill., Dec. 11, 2023 /PRNewswire/ -- The esteemed Dr. Faris Abusharif Scholarship for Medical Students is now accepting applications, offering a significant opportunity for budding medical professionals to propel their academic journey.
  • This exclusive scholarship, with a one-time award of $1500, is designed to assist students enrolled in accredited medical schools in the United States.
  • How will the Dr. Faris Abusharif Scholarship for medical students help you to achieve your goals?"
  • This scholarship represents a beacon of hope for aspiring medical professionals, propelling their ambitions and fostering the ideals of compassion, dedication, and academic excellence set forth by Dr. Faris Abusharif.

The Inner Circle Acknowledges, Kathryn Ray as a Pinnacle Life Member for her contributions to the fields of Obstetrics and Gynecological

Retrieved on: 
Lunedì, Novembre 13, 2023
Inner circle, Woman, Physician, Tubing (recreation), Student, Pregnancy, Multimedia, American Medical Association, American College, Obstetrics, Birmingham–Southern College, Vagina, Chicago Medical School, Mental Disability Advocacy Center, MD, Uterus, Society, Education, Puberty, Nursing, Science, Mathematics, Gynaecology

ARLINGTON HEIGHTS, Ill., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Kathryn Ray is acknowledged as a Pinnacle Life Member for her contributions to the fields of Obstetrics and Gynecological.

Key Points: 
  • ARLINGTON HEIGHTS, Ill., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Kathryn Ray is acknowledged as a Pinnacle Life Member for her contributions to the fields of Obstetrics and Gynecological.
  • Dr. Ray pursued higher education at Birmingham Southern College in Birmingham, Alabama where she earned a Bachelor of Science in Math and German.
  • Board-certified in obstetrics and gynecology, Dr. Ray is a specialist in reproductive care from puberty through adulthood, which may involve the female reproductive system, pregnancy, and childbirth.
  • Dr. Ray is a member of the American Medical Association (AMA); the Society for Laparoscopic Surgeons; and Fellow of the American College of Obstetrics and Gynecology.

The Ketamine Healing Clinic of Los Angeles and Orange County Introduces an Innovative Approach: Combining Deep TMS and Ketamine Therapy

Retrieved on: 
Giovedì, Ottobre 12, 2023
Transcranial magnetic stimulation, TMS, Multimedia, Twilight anesthesia, Anxiety, Brain, Chicago Medical School, Field line, Insurance, Ketamine, University, LOS, Patient, Mental health, IV, Maintenance, OCD, Depression, Medical Center, USC, Mevalonate pathway, Quality of life, Medical imaging, Pharmaceutical industry, Hospital

LOS ANGELES, Oct. 12, 2023 /PRNewswire-PRWeb/ -- Spearheaded by the esteemed Dr. David Mahjoubi, this groundbreaking approach has the potential to revolutionize the field of mental health by offering amplified therapeutic benefits for individuals suffering from depression, anxiety, OCD and smoking addiction. Deep TMS, a non-invasive procedure that uses magnetic fields to stimulate specific areas of the brain, has long been recognized as an effective treatment for various mental health conditions. Ketamine therapy, on the other hand, has gained significant attention in recent years for its rapid and profound effects. By combining these two powerful modalities, Dr. Mahjoubi and his team at the Ketamine Healing Clinic of Los Angeles and Orange County are paving the way for a new era of mental health treatment. This unique combination of deep TMS and ketamine therapy synergistically targets the brain's neural pathways and may provide faster and longer-lasting relief, ultimately improving the quality of life for countless individuals.

Key Points: 
  • The Ketamine Healing Clinic of Los Angeles and Orange County is proud to announce the introduction of an innovative treatment protocol that combines deep transcranial magnetic stimulation (TMS) and ketamine therapy.
  • By combining these two powerful modalities, Dr. Mahjoubi and his team at the Ketamine Healing Clinic of Los Angeles and Orange County are paving the way for a new era of mental health treatment .
  • For information on the Ketamine Healing Clinic of Los Angeles and the Ketamine Healing Clinic of Orange County please visit the website at http://www.ketaminehealing.com , or call (424) 278-4241 or (949) 514-8261.
  • Dr. David Mahjoubi, The Ketamine Healing Clinic of Los Angeles, (424) 278-4241, [email protected] , https://www.ketaminehealing.com/
    View original content to download multimedia: https://www.prweb.com/releases/the-ketamine-healing-clinic-of-los-angele...

Alterome Therapeutics Welcomes Andrew S. Chi, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Mercoledì, Agosto 23, 2023
General Health, Health, Oncology, Glioma, Molecular biology, BioNTech, KRAS, Huangshan, Translation, Broad Institute, Drug development, Biochemistry, Epigenomics, Cone Health Women's Hospital, CSO, Mirati Therapeutics, Chicago Medical School, Cancer, Drug, Clinical Cancer Research, Lung cancer, Rosalind Franklin University of Medicine and Science, MIT, Boston University, Harvard University, Harvard Medical School, Neuro, Managing editor, Mirati, Neurology, Hospital, Research, FDA, Massachusetts General Hospital, Therapy, Neon, Dana–Farber Cancer Institute, Pharmaceutical industry, Science

Alterome Therapeutics, Inc. , a next-generation precision oncology company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the appointment of Andrew S. Chi, M.D., Ph.D., as its Chief Medical Officer.

Key Points: 
  • Alterome Therapeutics, Inc. , a next-generation precision oncology company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the appointment of Andrew S. Chi, M.D., Ph.D., as its Chief Medical Officer.
  • “We are excited to welcome Andrew to Alterome during this important phase as we advance our first two programs into the clinic next year,” said Eric Murphy, Ph.D., co-founder, CEO and CSO of Alterome Therapeutics.
  • “Andrew is a talented physician-scientist who brings considerable expertise across all stages of oncology drug development spanning clinical and translational research through global Phase III studies.
  • Before that, he was Senior Director, Clinical Development, at Neon Therapeutics, which was acquired by BioNTech.